Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2022 08:00 ET | Source: Baudax Bio, Inc.

Baudax Bio Regains Compliance with NASDAQ Listing Requirements

MALVERN, Pa., March 07, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings,...
March 02, 2022 07:00 ET | Source: Baudax Bio, Inc.

Baudax Bio Announces Seventh Orange Book Listable Patent for ANJESO®

MALVERN, Pa., March 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today...
February 24, 2022 23:23 ET | Source: Baudax Bio, Inc.

Baudax Bio Announces Pricing of $10.0 Million Public Offering

MALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on commercializing and developing innovative...
February 24, 2022 16:40 ET | Source: Baudax Bio, Inc.

Baudax Bio Announces Proposed Public Offering of Securities

MALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on commercializing and developing innovative...
February 15, 2022 20:29 ET | Source: Baudax Bio, Inc.

Baudax Bio Announces 1-for-35 Reverse Stock Split

MALVERN, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today...
January 04, 2022 07:00 ET | Source: Baudax Bio, Inc.

Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

MALVERN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today...
December 31, 2021 16:05 ET | Source: Baudax Bio, Inc.

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care...
December 28, 2021 08:00 ET | Source: Baudax Bio, Inc.

Baudax Bio Announces $4.2 Million Registered Direct Offering

MALVERN, Pa., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care...
November 15, 2021 07:00 ET | Source: Baudax Bio, Inc.

Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today...
November 11, 2021 07:00 ET | Source: Baudax Bio, Inc.

Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000

BX-1000 Completes Dose-Escalation Study; Was Generally Well Tolerated and Rapidly Achieved Muscle Paralysis, Along with Complete Spontaneous Recovery BX-2000 and BX-3000 to Advance Into Clinical...